CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 135 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,337 | +36.2% | 1,364 | 0.0% | 0.01% | +57.1% |
| Q2 2023 | $14,936 | +25.6% | 1,364 | 0.0% | 0.01% | +16.7% |
| Q1 2023 | $11,894 | +36.4% | 1,364 | -1.9% | 0.01% | +20.0% |
| Q4 2022 | $8,722 | +74.4% | 1,391 | -6.5% | 0.01% | +66.7% |
| Q3 2022 | $5,000 | +25.0% | 1,487 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $4,000 | +100.0% | 1,487 | +104.5% | 0.00% | +100.0% |
| Q4 2021 | $2,000 | -33.3% | 727 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $3,000 | 0.0% | 727 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $3,000 | 0.0% | 727 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $3,000 | +200.0% | 727 | +127.9% | 0.00% | +100.0% |
| Q4 2020 | $1,000 | 0.0% | 319 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,000 | -66.7% | 319 | -42.8% | 0.00% | -50.0% |
| Q3 2019 | $3,000 | -25.0% | 558 | -10.3% | 0.00% | -33.3% |
| Q2 2019 | $4,000 | -50.0% | 622 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $8,000 | +14.3% | 622 | -2.5% | 0.01% | +100.0% |
| Q3 2018 | $7,000 | – | 638 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |